What is monkeypox? Is monkeypox really that alarming? Why pay close attention to monkeypox-related stocks?
Let's first look at the recent news:
News One:
On August 4, the Biden administration in the United States declared a public health emergency due to the monkeypox outbreak. According to data from the U.S. Centers for Disease Control and Prevention, as of August 3, the confirmed cases of monkeypox in the U.S. reached 6,617. With the exception of Montana and Wyoming, 48 states across the U.S. have reported related cases. Currently, monkeypox vaccines are in short supply across the country. The U.S. federal government is distributing approximately 1.1 million doses of the monkeypox vaccine, while health officials estimate that around 3.5 million doses are needed to combat the outbreak. The next batch of 500,000 doses is expected to be delivered in October. Moreover, according to U.S. federal government data, most of the vaccines ordered by the country will not be delivered until 2023.
News Two:
On July 23, the World Health Organization announced that the monkeypox outbreak constitutes a Public Health Emergency of International Concern. According to Global Health data, as of August 3, a total of 26,208 confirmed monkeypox cases have been reported across 87 countries and regions globally; the number of cases is still in an accelerating growth phase, doubling within two weeks. Although the current mortality rate of monkeypox remains low, fatal cases have been reported in Brazil, Spain, India, and Peru.
The COVID-19 pandemic has brought immense profits to pharmaceutical companies in the United States, with significant earnings generated specifically from the pandemic-related sector. $Pfizer (PFE.US)$ So, could this monkeypox outbreak lead to similar outcomes...